Changeflow GovPing Healthcare FDA Acknowledgement Letter to Steranco Healthca...
Routine Notice Added Final

FDA Acknowledgement Letter to Steranco Healthcare Pvt. Ltd.

Email

Summary

The Food and Drug Administration (FDA) has issued an acknowledgement letter to Steranco Healthcare Pvt. Ltd. The letter confirms receipt of documentation related to a submission. No specific details regarding the nature of the submission or any required actions are provided in the available information.

Published by FDA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The FDA has issued an acknowledgement letter to Steranco Healthcare Pvt. Ltd., confirming receipt of a submission. The document, identified by docket number FDA-2026-P-3202-0002, is an administrative notice from the FDA's Center for Drug Evaluation and Research (CDER).

As this is an acknowledgement letter, it does not impose new requirements or deadlines on regulated entities. Compliance officers should note the docket number for tracking purposes if Steranco Healthcare's submission is a matter of ongoing regulatory interest. No specific actions are required based solely on this acknowledgement.

Archived snapshot

Mar 28, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

There are no documents available to view or download

Attachments 1

Acknowledgement Letter from FDA DMB to Steranco Healthcare Pvt. Ltd.

More Information
- Author(s) CDER
Download

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
FDA-2026-P-3202-0002
Docket
FDA-2026-P-3202-0002

Who this affects

Applies to
Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Manufacturing
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Compliance
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Drug Manufacturing

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!